- Glow LifeTech Corp. (CSE:GLOW) has provided an update on its commercial operations, cannabis activities and clinical studies in relation to its MyCell-enhanced products
- The company said it is focused on the final stages of developing its proprietary CBD and THC water-soluble ingredients for its Canadian launch
- Glow LifeTech has also been developing a diverse portfolio of high bioavailability cannabis ingredients and additional proprietary technologies to expand its portfolio of solutions
- Shares of Glow LifeTech opened trading at C$0.105
Glow LifeTech Corp. (GLOW) has provided an update to its operations, cannabis-related activities and clinical studies for its MyCell-enhanced products.
The MyCell Technology is an advanced delivery system that transforms poorly absorbed cannabinoids, like CBD and THC, into water-soluble concentrates that have fast-acting onset, high absorption and precise dosing.
In a press release, the company said it is currently focused on the final stages of developing its proprietary CBD and THC water-soluble ingredients as it prepares to launch the products in Canada.
Similarly, now that Glow LifeTech’s licensed cannabis processing space now built and the successful commissioning of equipment earlier in the year, the company has been developing a diverse portfolio of high-bioavailability cannabis ingredients and proprietary technology to expand its portfolio.
“We are excited to be in the final stages of development of our proprietary cannabis ingredients, after facing considerable COVID-related supply chain delays in 2021,” Tom Glawdel, CEO of Glow LifeTech, said in a press release.
“Our MyCell® enhanced ingredients are well-positioned to unlock a new era of more effective, fast-acting and great tasting products and we look forward to our commercial launch throughout North America.”
The company is also in the late stages of a rebranding identity that will reflect the quality of its technology and products.
Shares of Glow LifeTech opened trading at C$0.105.
